Popular anti-platelet therapy reduces risk of cardiovascular events in men and women
Tuesday, November 10, 2009 - 08:21
in Health & Medicine
A new study, published in the November 17, 2009, issue of the Journal of the American College of Cardiology, adds to a growing body of research seeking to evaluate and understand possible sex differences associated with antiplatelet therapies. This study--the first to look at the impact of clopidogrel, one of the most frequently prescribed drugs to prevent and treat heart disease, in women--found it to be effective in reducing cardiovascular (CV) events in both men and women with no statistically significant sex differences in terms of expected clinical benefit or increased harm.